PLANTOGRAM · CLINICIAN EDUCATION
Multi-Pathway Treatment Rationale
Explore the scientific rationale for considering cannabinoid therapy within wider neurological, immune, metabolic and behavioural care.
The endocannabinoid system in a wider network
The endocannabinoid system is discussed in the source as part of an interconnected regulatory network. The rationale considers neurological, immune, endocrine, metabolic and inflammatory factors alongside pain, mood, sleep and cognition. The document calls this wider perspective the Treatment Stack.
It proposes that cannabinoids may be considered alongside selected complementary ingredients and conventional, behavioural or lifestyle interventions. Any benefit depends on the specific intervention, dose, patient and supporting evidence.
From receptors to clinical questions
The source discusses CB1 and CB2 alongside TRPV1, PPARs, serotonin-related targets, GPR55, adenosine, glycine receptors and inflammatory signalling. These mechanisms provide research context. They do not demonstrate that a commercial combination will improve a particular condition.
The useful clinical question is whether a proposed intervention addresses a relevant problem with evidence, acceptable risk and measurable benefit.
Components of the proposed framework
The source includes cannabinoids, endocannabinoid-like compounds such as PEA, terpenes, lifestyle changes, exercise, nutrition, sleep optimisation, stress management, behavioural therapies, conventional medicines and consideration of metabolic or inflammatory disease. Gut health and the gut–brain axis appear as research and assessment domains rather than universal treatment targets.
How to evaluate a combination
Review human evidence, pharmacological compatibility, stability, safety and intended clinical use. Distinguish evidence for an individual ingredient from evidence for the finished formulation. A multi-target hypothesis can guide research, but does not establish synergy or superiority.
A systems-based assessment may support a single therapy, a combination, non-drug care or referral. The number of ingredients is not a measure of treatment quality.
Source resource
Download Multi-Pathway Treatment Rationale
Further reading
- TGA: accessing medicinal cannabis for a patient
- TGA: information directed exclusively to health professionals
